Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Neoplasm
100%
Serous Carcinoma
72%
Precancerous Condition
72%
Endometrial Cancer
55%
Endometrium
52%
Malignant Neoplasm
52%
Endometrium Carcinoma
48%
Gestagen
47%
Adenocarcinoma
43%
Morphology
41%
Ovarian Cancer
39%
Wart Virus
35%
Fallopian Tube
35%
Carcinoma
35%
Protein P53
34%
Precursor
33%
Immunohistochemistry
33%
Diagnosis
31%
Endometrioid Carcinoma
30%
Krukenberg Tumor
29%
Catenin
28%
Biological Marker
28%
Carcinogenesis
27%
Clear Cell Carcinoma
26%
Cytotechnology
24%
Dysplasia
24%
Metastatic Carcinoma
23%
Biopsy
22%
Endometriosis
22%
Pelvis
22%
Pathologist
21%
Prevalence
20%
Disease
18%
Cancer
18%
Intraepithelial Neoplasia
17%
Atypical Hyperplasia
17%
Epithelioma
17%
Endometrial Hyperplasia
16%
Inhibin
16%
Recurrent Disease
15%
Progesterone Receptor
12%
Cancer Cell
12%
P16
12%
Differential Diagnosis
12%
Carcinoma in Situ
12%
Dysgerminoma
12%
Gene Mutation
12%
Neoadjuvant Chemotherapy
12%
Endometrial Polyp
12%
Human Papillomavirus Type 16
11%
Keyphrases
Endometrial Cancer
38%
Tumor
30%
Endometrial Serous Carcinoma
29%
Endometrium
28%
Serous Carcinoma
22%
Fallopian Tube
22%
Progestin
22%
Precancer
20%
Endometrial Precancer
18%
Catenin
17%
Ovarian Epithelial Cancer
17%
Progestin Therapy
16%
Endometrial Carcinoma
16%
Endometrial Glandular Dysplasia
16%
PAX2
16%
High-risk Human Papillomavirus (HR-HPV)
14%
Endometriosis
13%
Progesterone Resistance
13%
Pathologist
12%
Precursor Lesions
12%
Precancerous Lesions
12%
Endometrioid
12%
Endometrial Hyperplasia
11%
Carcinoma in Situ
11%
Immunohistochemistry
11%
Inhibin
10%
Immunohistochemical Staining
9%
Adenomyosis
9%
Endometrial Clear Cell Carcinoma
9%
Serous Endometrial Intraepithelial Carcinoma
9%
Neoplasia
9%
Programmed Death-ligand 1 (PD-L1)
9%
Nuclear Factor Erythroid 2-related Factor 2 (Nrf2)
8%
Epithelial Inclusion
8%
Residual Disease
8%
Serous
8%
Pelvic Serous Carcinoma
8%
Ovarian Cancer
7%
Atypical Hyperplasia
7%
Uterine Serous Carcinoma
7%
Endometrioid Carcinoma
7%
Molecular Features
7%
Overexpression
7%
Combined Positive Score
6%
Immunoreactivity
6%
Secretory Cells
6%
High Risk
6%
Oncofetal Antigen
6%
Prognostic Significance
6%
Interleukin-8
6%